Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial
Dariusz Dudek, Yoshinobu Onuma, John A Ormiston, Leif Thuesen, Karine Miquel-Hebert, Patrick W Serruys, Dariusz Dudek, Yoshinobu Onuma, John A Ormiston, Leif Thuesen, Karine Miquel-Hebert, Patrick W Serruys
Abstract
Aim: The first-in-man ABSORB Cohort A trial demonstrated the bioresorption of the ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA) at two years. This report describes the 4-year clinical outcomes.
Methods and results: The ABSORB Cohort A trial enrolled 30 patients with a single de novo native coronary artery lesion. Clinical follow-up was available in 29 patients since one patient withdrew consent after the six month follow-up. At four years, the hierarchical ID-MACE of 3.4% remained unchanged. Clopidogrel therapy had been discontinued in all patients.
Conclusion: Four-year clinical results demonstrate a sustained low MACE rate (3.4%) without any late complications such as stent thrombosis.
Trial registration: ClinicalTrials.gov NCT00300131.
Source: PubMed